SYDNEY--(BUSINESS WIRE)--SpeeDx have announced signing two new distribution partners, creating comprehensive access for customers to market-leading SpeeDx ResistancePlus® and PlexPCR® tests across Europe. AB ANALITICA will distribute throughout Italy and Immuno Diagnostic Oy will cover Finland.
“Our new distribution partners have strong sales presence in their regions and close working relationships with the key customers that are interested in our solutions,” says Colin Denver, SpeeDx CEO. “Antibiotic resistance in sexually transmitted diseases is a top concern for authorities and testing bodies across Europe, and now more laboratories can access our ResistancePlus tests for Mycoplasma genitalium and gonorrhoea to help address the real need for Resistance Guided Therapy.”
The SpeeDx ResistancePlus portfolio includes ResistancePlus GC* (CE-IVD) - the first commercially available test that combines Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility. ResistancePlus GC enables stewardship of last-line antibiotic treatments by directing therapy towards ciprofloxacin when appropriate. Ciprofloxacin is a simple oral antibiotic, and surveillance data indicates it is still effective for up to 70% of gonorrhoea infections.1-4 The market-leading ResistancePlus MG assay from SpeeDx simultaneously detects Mycoplasma genitalium and genetic markers for azithromycin resistance, with demonstrated clinical outcomes of increased patient cure rate up to 92% compared with 40% cure rates when using MG-detection-only testing.5 SpeeDx also plans to release a new ResistancePlus MG test for resistance markers linked to second-line antibiotic treatment failure.
The SpeeDx portfolio also includes PlexPCR VHS - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further tests in the PlexPCR portfolio include plans for a comprehensive multiplex panel for respiratory virus testing as well as a respiratory bacterial infection testing solution.
*available where CE-mark is accepted, not available in the U.S. or A.U.
1. Harris SR et al. Lancet Infect Dis Published online May 15th 2018.
2. Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015
3. Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5
4. Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19
5. Read TRH. et al CID June 5 2018 doi.org/10.1093/cid/ciy477.
Founded in 2009, SpeeDx is an Australian-based private company with
offices in London and the US, and distributors across Europe. SpeeDx
specializes in molecular diagnostic solutions that go beyond simple
detection to offer comprehensive information for improved patient
management. Innovative real-time polymerase chain reaction (qPCR)
technology has driven market-leading multiplex detection and priming
strategies. SpeeDx has a portfolio of CE-IVD kits for detection of
infectious disease pathogens, sexually transmitted infection (STI), and
antimicrobial resistance markers and is currently conducting clinical
trials for FDA clearance in 2019. SpeeDx ResistancePlus
tests enable Resistance Guided Therapy, improving patient outcomes by
empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com